Influenza virus neuraminidase: Structure, antibodies, and inhibitors

Protein Science

Volumn 3, Issue 10, 1994, Pages 1687-1696

  Colman, P M ^a  

^a BIOMOLECULAR RESEARCH INSTITUTE   (Australia)

Author keywords

antigenic variation; antigen antibody interactions; drug design; enzyme inhibition

Indexed keywords

ENZYME INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGENIC VARIATION; ANTIVIRAL ACTIVITY; CRYSTALLOGRAPHY; DRUG DESIGN; ENZYME INHIBITION; ENZYME STRUCTURE; INFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW;

INFLUENZA VIRUS;

EID: 0028113435     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.5560031007     Document Type: Article

References (69)

1. Mucus — A protective secretion of complexity
2. Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding
3. Influenza B virus neuraminidase can synthesize its own inhibitor
4. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid
5. Mucins and mucoids in relation to influenza virus action. IV. Inhibition by purified mucoid of infection and haemagglutinin with the virus strain WSE
6. Mucin as a substrate of enzyme action by viruses of the mumps influenza group
7. Evidence for a sialosyl cation transition‐state complex in the reaction of sialidase from influenza virus
8. Domain association in immunoglobulin molecules. The packing of variable domains
9. Structure of antibody‐antigen complexes: Implications for immune recognition
10. Influenza virus neuraminidase: Enzyme and antigen
11. Sequence and structure alignment of paramyxovirus haemagglutinin‐neuraminidase (HN) with influenza virus neuraminidase
12. The three dimensional structure of a complex of antibody with influenza virus neuraminidase
13. Structure of the catalytic and antigenic sites in influenza virus neuraminidase
14. The specificity of viral and bacterial sialidases for 2–3 and 2–6 linked sialic acids in glycoproteins
15. The specificity of viral sialidases. The use of oligosaccharide substrates to probe enzyme characteristics and strain specific differences
16. Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase
17. Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin‐like domains in addition to the catalytic domain
18. Fusion mutants of the influenza virus haemagglutinin glycoprotein
19. Antibody structure
20. The inhibition of neuraminidase and antiviral action
21. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
22. Neuraminidase: Its substrate and mode of action
23. Historical introduction
24. Effects of hexose starvation and the role of sialic acid in influenza virus release
25. Effect of cytochalasin B on the maturation of enveloped viruses
26. Affinity ranking of influenza neuraminidase mutants with monoclonal antibodies using an optical biosensor. Comparison with ELISA and slot blot assays
27. The molecular basis of the specific anti‐influenza action of amantadine
28. Update on antiviral agents and viral drug resistance
29. Recovery of drug‐resistant influenza A virus during therapeutic use of rimantadine
30. An autoantibody to single‐stranded DNA: Comparison of the three‐dimensional structures of the unliganded Fab and a deoxynucleotide‐Fab complex
31. Adsorption of influenza haemagglutinins and virus by red blood cells
32. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2‐deoxy‐2,3‐didehydro‐N‐acetylneuraminic acid modified at the C‐4 position
33. Antiviral activity of antiserum specific for an influenza virus neuraminidase
34. Three dimensional structure of an antigenic mutant of the influenza virus haemagglutinin
35. Recombinant anti‐sialidase single‐chain variable fragment antibody. Characterization, formation of dimer and higher‐molecular‐mass multimers and the solution of the crystal structure of the single‐chain variable fragment/si‐alidase complex
36. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures
37. Crystallisation and peptide maps of neuraminidase heads from H2N2 and H3N2 influenza virus strains
38. Shape complementarity at protein‐protein interfaces
39. Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein
40. Recombinant antineuraminidase single chain antibody: Expression, characterization, and crystallization in complex with antigen
41. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody
42. Inhibition of neuraminidase activity by derivatives of 2‐deoxy‐2,3‐dehydro‐N‐acetylneuraminic acid
43. 2‐Deoxy‐2,3‐dehydrosialic acids. I. Synthesis and properties of 2‐deoxy‐2,3‐dehydro‐N‐acylneuraminic acids and their methyl esters
44. Inhibition of influenza virus replication in tissue culture by 2‐deoxy‐2,3‐dehydro‐N‐trifluoro‐acetyl‐neuraminic acid (FANA): Mechanism of action
45. Inhibitors of viral neuraminidase as potential antiviral drugs
46. Characterisation of temperature sensitive influenza virus mutants defective in neuraminidase
47. Newcastle disease virus contains a linkage‐specific glycoprotein sialidase
48. Slow‐binding inhibition of sialidase from influenza virus
49. 2 protein has ion channel activity
50. Immunology of influenza
51. Variation in influenza virus genes. Epidemiological, pathogenic, and evolutionary consequences
52. Major antigen‐induced domain rearrangements in an antibody
53. Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants
54. Refined crystal structure of the influenza virus N9 neuraminidase‐NC41 Fab complex
55. Crystal structures of two mutant neuraminidase‐antibody complexes with amino acid substitutions in the interface
56. Three‐dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution
57. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
58. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor
59. The structure of an escape mutant of the glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 Å
60. Rational design of potent sialidase‐based inhibitors of influenza virus replication
61. Sugar residues on proteins
62. Chemical and antigenic characterisation of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidase
63. Antigenic structure and variation in an influenza N9 neuraminidase
64. Selection and analysis of antigenic variants of the neuraminidase of N2 influenza virus with monoclonal antibodies
65. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid
66. Structure, function, and antigenicity of the hemagglutinin of influenza virus
67. Membrane fusion proteins of enveloped animal viruses
68. Man made antibodies
69. 4‐Guanidino‐2,4‐dideoxy‐2,3‐dehydro‐N‐acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro